Immunome rises after positive data from experimental tumor treatment

Immunome

15/12/2025 12:41

** Shares of drug developer Immunome IMNM.O jump 30.3% to $25.5 in premarket trading

** Co says its experimental treatment met the main goal of a late-stage trial

** Co was testing the drug, varegacestat, in patients with progressing desmoid tumors

** Desmoid tumors are noncancerous tumors that arise from connective tissue

     ** The drug showed a 84% reduction in the risk of disease progression or death compared to placebo in the trail

** Varegacestat was generally well tolerated, with a manageable safety profile - IMNM

** Up to last close, stock up 84.3% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))